Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 16Squamous Cell Carcinoma of Head and Neck 13Neoplasms 9Stomach Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Endometrial Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Oropharyngeal Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3HER2-positive Breast Cancer 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2Solid Tumors 2Sarcoma 2

Interventions

Prednisone 2Abiraterone Acetate 2fludrocortisone acetate 1enzalutamide 1darolutamide 1apalutamide 1Standard of Care 1Radiosurgery 1Hydrocortisone 1Docetaxel 1Dexamethasone 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Cancer Metastatic × Docetaxel × 90 days × Clear all
NCT02913196 2026-04-20

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

Weill Medical College of Cornell University

Phase 1 Completed
16 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡